Medical Therapy. Pharmacokinetics and Pharmacology

Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study

Claudia R. Morris, Frans A. Kuypers, Robert Hagar, Sandra Larkin, Lisa Lavrisha, Augusta Saulys, Elliott P. Vichinsky, Jung H. SuhEmory University School of Medicine and Children’s Healthcare of Atlanta. UCSF-Benioff Children’s Hospital Oakland.United States Complementary Therapies in MedicineComplement Ther Med 2022; 64: DOI: 10.1016/j.ctim.2022.102803 AbstractObjectives: L-Glutamine is FDA-approved for sickle cell disease (SCD), yet the mechanism(s)-of-action are […]

Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study Read More »

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension

Candice D. Fike, Charul Avachat, Angela K. Birnbaum, Judy L. Aschner, Catherine M. SherwinUniversity of Utah Health. University of Minnesota. Hackensack Meridian School of Medicine. Wright State University Boonshoft School of Medicine and Dayton Children’s Hospital.United States Paediatric DrugsPaediatr Drug 2023; 25: 87-96DOI: 10.1007/s40272-022-00542-x AbstractBackground: Options to treat pulmonary hypertension (PH) in neonates with bronchopulmonary dysplasia (BPD)

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Read More »

Targeted treprostinil delivery inhibits pulmonary arterial remodeling

Aijun Liu, Bin Li, Ming Yang, Yongying Shi, Junwu SuBeijing Anzhen Hospital. The First Affiliated Hospital of Guangzhou Medical University. China European Journal of PharmacologyEur J Pharmacol 2022; 923: DOI: 10.1016/j.ejphar.2021.174700 AbstractIntroduction: Pulmonary arterial hypertension (PAH) is a fatal disease caused by the progressive remodeling of pulmonary arteries (PAs). Treprostinil (TPS) is a tricyclic benzidine prostacyclin clinically

Targeted treprostinil delivery inhibits pulmonary arterial remodeling Read More »

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study

Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study Read More »

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension

Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, Dorina van der Mey, Gagriela Wirsching, Yang Zhang, Henk-Jan Drenth, Anne Keunecke, Esmée Vendel, Soundos SalehBayer AG. LAP&P Consultants.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 908-917DOI: 10.1002/ppul.26277 AbstractBackground: The PATENT-CHILD study investigated riociguat in children aged ≥ 6 to <18 years with pulmonary arterial hypertension (PAH) treated with tablets or an

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension Read More »

Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data

Malek Okour, Mita M. Thapar, Colm Farrell, Mary Ann Lukas, Maurice Beghetti, Misba BeeraheeGlaxo Smith Kline. ICON Clinical Research. University of Geneva and Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pédiatrique.United States, United Kingdom and Switzerland Journal of Clinical PharmacologyJ Clin Pharmacol 2022; DOI: 10.1002/jcph.2199 AbstractThis study aimed to develop a population pharmacokinetic (PK) model

Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data Read More »

Scroll to Top